

## Genetic Defects in *SHROOM3* Lead to Congenital Heart Defects

Samuel Lorentz<sup>1</sup>, Matthew D Durbin, MD, MS<sup>2</sup>, Stephanie Ware, MD, PhD<sup>2,3</sup>

<sup>1</sup>Indiana University School of Medicine, <sup>2</sup>Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, <sup>3</sup>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN

**Background and Hypothesis:** Congenital heart disease (CHD) is the most common birth defect, but most genetic contributors remain unknown. We recently identified CHD patients with variants in a gene called *SHROOM3*. The *SHROOM3* protein impacts the actin cytoskeleton by binding ActinF and Rho-kinase, causing actomyosin constriction. *SHROOM3* also binds Dishevelled2 (Dvl2), a component of Wnt/Planar cell polarity (PCP) signaling pathway, suggesting a connection between PCP signaling and actin-myosin contraction. We hypothesize *SHROOM3* disruption alters PCP signaling and actin cytoskeleton during cardiac development, and is a novel contributor to CHD.

**Project Methods:** We analyzed the cardiac phenotype of *Shroom3* gene trap knockout mice at embryonic day 14.5. We characterized the expression of *Shroom3* during cardiac development using LacZ staining at important stages of cardiac development. Using IHC, we measured actomyosin disruption in *Shroom3* knockout embryos. We performed in silico analysis on previously identified *SHROOM3* variants from patients with CHD.

**Results:** *Shroom3* null mice had Ventricular Septal Defects (0.73,  $p=0.0006$ ), Double Outlet Right Ventricle (0.33,  $p=0.04$ ), Left Ventricular Noncompaction, and other CHD. *Shroom3* mutant mice left ventricular wall thickness was 36% thinner compared to wild type mice ( $99.0\pm 8.6\mu\text{m}$ ,  $63.0\pm 8.4\mu\text{m}$ ,  $p=0.005$ ). LacZ shows the expression of *Shroom3* through important stages of cardiac development, and IHC shows actomyosin disruption. In silico analysis demonstrates CHD patients have *SHROOM3* variants in highly conserved nucleic acid and protein sequences, and significant protein structural changes.

**Conclusion and Potential Impact:** *Shroom3* null mice have cardiac defects resembling a Wnt/PCP disruption phenotype. Similarly, patients with CHD have likely pathogenic variants in *SHROOM3*. These data support a role for *SHROOM3* in CHD pathogenesis and begin to elucidate mechanisms. Identifying *SHROOM3*'s role in CHD is critical to understanding cardiac development as well as the diagnosis, management and treatment of CHD.